Company intelligence / Profile preview

ScalmiBio

San Carlos, California, United States

Ownership: Public · ALXO
Development stage: Other

Overview

ScalmiBio developed a conditional activation platform for antibody prodrugs to increase tumor specificity and reduce toxicity; preclinical proof-of-concept was achieved, leading to acquisition by ALX Oncology.

Therapeutic areas: Oncology
Modalities: AntibodyAntibody-drug conjugate
Industry: Biotech

Partnerships

None disclosed prior to acquisition; focus was on non-dilutive funding and strategic acquisition

Beyond the preview

Go deeper on ScalmiBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScalmiBio.

Explore the full profile